NetworkNewsBreaks – Zosano Pharma Corp.’s (NASDAQ: ZSAN) M207 Meets Co-primary Endpoints in Efficacy Trial; Shares Skyrocket
Shares of Zosano Pharma (NASDAQ: ZSAN) soared more than 100% this morning on news that the company’s lead product candidate, M207, achieved both co-primary endpoints in the recently completed ZOTRIP trial. The ZOTRIP pivotal efficacy study compared three doses (1.0mg, 1.9mg and 3.8mg) of M207, a novel transdermal therapeutic, to placebo for a single migraine attack. The 3.8mg dose achieved significance in the secondary endpoints of pain freedom at 45 minutes and one hour and showed durability of effect on pain freedom at 24 and 48 hours. Overall, higher pain freedom rates were achieved on all doses after 60 minutes…







